BSD Medical is Now Pyrexar Medical

Pyrexar Medical would like to congratulate Ruediger Wessalowski, MD, and Chris Diederich, Ph.D., for the recent honors awarded them at this year's Society for Thermal Medicine annual conference held in Florida last week.

Dr. Ruediger Wessalowski awarded the prestigious J. Eugene Robinson Award. The J. Eugene Robinson Award is presented each year to an investigator who has made outstanding contributions to hyperthermic oncology. Dr. Wessalowski practices at the Clinic for Pediatric Oncology, Hematology, and Clinical Oncology at the Heinrich-Heine-University (HHU) located in Düsseldorf, Germany. He is honored for his work in pioneering caring and innovative cancer treatment solutions for children and his continuing advancements in hyperthermia best practices.  HHU uses the Pyrexar BSD-500, BSD-2000, and the BSD-2000 3D/MR Hyperthermia systems.

Chris Diederich, Ph.D., was honored with the George M. Hahn Award. The George M. Hahn Award is presented every other year to an investigator whose research has contributed in a significant way to new clinical applications in thermal therapy. Professor Diederich is the Director of Clinical Hyperthermia Physics and Thermal Therapy Research at the University of California, San Francisco. The Pyrexar BSD-500 and BSD-2000 hyperthermia systems are in practice at the UCSF Helen Diller Family Comprehensive Cancer Center.

About STM
Founded in 1986, the Society of Thermal Medicine is a premier, international scientific forum for fostering interaction and innovation in the study of biological, physical and medical applications of thermal therapy for cancer and other diseases and for facilitating a greater fundamental understanding of the role of temperature in cellular and molecular function.

Dr. Sennewald Medizintechnik, Pyrexar's European distribution partner,  has brought together an impressive program of clinicians to talk about hyperthermia's role in the treatment of cancer, at this years ESTRO 38 (European Society for Radiotherapy & Oncology).  The luncheon symposium titled "Hyperthermia in the age of personalized oncology" will be held Saturday, April 27th, and is open to all ESTRO attendees (space is limited).

Program outline below:

ABOUT ESTRO

Founded in 1980, ESTRO, the European SocieTy for Radiotherapy & Oncology, is a non-profit and scientific organization that fosters the role of Radiation Oncology to improve patients’ care in the multimodality treatment of cancer. ESTRO 38 is held in Milan, Italy, April 26th - 30th, 2019, at the Milan Convention Center.

It is a busy Spring for Pyrexar at the upcoming Conference Events in the US and Europe.  These conferences are a gathering of the best in radiation oncology and hyperthermia experts and an excellent resource for those interested in the field of thermal oncology.  We will be exhibiting, either directly or via our distribution partners, at the following events

The 36th Annual Meeting of the Society for Thermal Medicine, 33rd Annual Meeting of the European Society for Hyperthermic Oncology, 20th Congress of the Spanish Society of Radiation Oncology, and the 2019 American Brachytherapy Society Annual Meeting will provide an arena for presentations of latest data, concepts, and breakthroughs in our ever-expanding understanding radiation oncology and thermal medicine in the context of engineering, physics, materials science, and biology.

Here are some dates to help you plan

New Hyperthermia Training Classes Added to STM (Society of Thermal Medicine)

• How to establish a hyperthermia program
• Practice guidelines for superficial hyperthermia
• Practice guidelines for deep hyperthermia
• Practice guidelines for interstitial hyperthermia
• Equipment, planning, and execution of MW superficial hyperthermia treatment
• Equipment, planning, and execution of RF deep hyperthermia treatment
• Assessment of hyperthermia treatments based on hypoxia imaging
• Clinical workflow, documentation, and reimbursement of hyperthermia treatments
• Impact of hyperthermia referrals in a Radiation Oncology Department

It has been four years since we acquired the hyperthermia division from BSD Medical and started Pyrexar Medical.  In addition to getting the technology rights to this life-changing technology, we also received a group of great, hardworking people. Pyrexar may be only celebrating year four, but we do this sitting atop four decades of drive, innovation, and the desire to give those that are battling cancer, a higher chance at disease-free survival.

We are looking toward achieving great strides in this next year. With that, we have many people to thank, and that includes you.  Thank you to all of our supporters, partners, researchers, physicians, physicists, radiation therapists, nurses, and administrative staff around the world. To those that continue to believe in the bright future of hyperthermia and to those who demand the best outcomes for their patients.

Thank you.